{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-005466","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.008283+00:00","generated_at":"2026-05-23T10:56:13.216159+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nasdaq Panel grants Lixte extension to July 3, 2025 for equity compliance","bullets":["Lixte received extension from Nasdaq Hearings Panel after April 3 hearing on equity deficiency.","Must demonstrate minimum $2.5M stockholders' equity by July 3, 2025 to remain listed.","Common stock (LIXT) and warrants (LIXTW) continue trading on Nasdaq during extension.","Company pursuing measures but warns no assurance of regaining compliance; delisting risk persists."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-005466","json":"https://secwatch.observer/filing/0001641172-25-005466.json","markdown":"https://secwatch.observer/filing/0001641172-25-005466.md","text":"https://secwatch.observer/filing/0001641172-25-005466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225005466/0001641172-25-005466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225005466/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T10:56:13.216159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea64dfef1cf4f3560eceb14e420fc85da3a35bec","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 17, 2025, the Company received notice that the Nasdaq Hearings Panel (the “Panel”) had granted the Company an extension in which to regain compliance with all continued listing rules of the Nasdaq Capital Market. The Panel’s determination follows a hearing on April 3, 2025, at which the Panel considered the Company’s plan to regain compliance with the Equity Rule. As a result of the extension, the Panel granted the Company’s request for continued listing on the Nasdaq Capital Market, provided that the Company demonstrates compliance with the Equity Rule and all other continued listing re","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225005466/0001641172-25-005466-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}